Trial · NCT06971965
Necessity of TSH Suppression Therapy in Active Surveillance for Thyroid Cancer Patients.
NCT06971965, Not applicable, Not yet recruiting, National Cancer Center, Korea
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Necessity of TSH Suppression Therapy in Active Surveillance for Thyroid Cancer Patients. Trials, record NCT06971965. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06971965
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Necessity of TSH Suppression Therapy in Active Surveillance for Thyroid Cancer Patients.
- NCT number
- NCT06971965
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 578 participants, estimated
- Lead sponsor
- National Cancer Center, Korea
- Conditions
- Thyroid Cancer, Papillary Thyroid Carcinoma
- Interventions
- Levothyroxin
- First posted
- 2025-05-14
- Last updated
- 2025-05-14
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of Disease progression | at 3,5years after enrollment | The rate of disease progression will be assessed as the proportion (%) of patients with biopsy-confirmed recurrence, based on suspicious findings identified through thyroid (neck) ultrasound performed at 6- to 12-month intervals. |
| Secondary | Disease free survival | at 3,5years after enrollment | As the time interval from enrollment to either disease progression or all-cause mortality, whichever occurs first. |
| Secondary | Disease specific survival | at 3,5years after enrollment | As the time from the date of enrollment to disease-specific mortality. |
| Secondary | Overall Survival | at 3,5years after enrollment | As the time from the date of enrollment to death. |
| Secondary | Target-TSH-level achievement rate | at 3,5years after enrollment | Comparison of between the low-TSH and high-TSH groups at each follow-up visit regarding the presence or absence of thyroid hormone use and its dosage, considering body weight and medication adherence, in order to achieve the target TSH concentration. |
| Secondary | Incidence of complications | at 3,5years after enrollment | Comparison of the incidence of complications at each follow-up visit between the low-TSH and high-TSH groups. |
| Secondary | Safety evaluation | at 3,5years after enrollment | Incidence and grade of adverse events. |
| Secondary | Risk Factors for Thyroid Cancer Recurrence | at 3,5years after enrollment | The study will assess the relationship between thyroid hormone levels (TSH, free T4, total T3 or free T3) and potential risk factors for recurrence, including: * Demographic factors: sex, age, smoking status, BMI * Pathologic features: tumor stage, size, extrathyroidal extension * Genetic mutations: BRAF, TERT promoter mutations The analysis will identify factors, adjusted for thyroid hormone levels, significantly associated with recurrence risk. Statistical methods such as Generalized Estimating Equations (GEE), Interval Censored Survival Analysis, and Cox-proportional hazards regression will be used for evaluation. |
| Secondary | Predictors of Treatment-Related Complications Based on Thyroid Hormone Levels | at 3,5years after enrollment | The study will assess the relationship between thyroid hormone levels (TSH, free T4, total T3 or free T3) and risk factors for treatment-related complications (e.g., tachycardia, reduced bone mineral density). Risk factors include: * Demographic factors: sex, age, smoking, BMI, weight, blood pressure, concurrent medications, menopausal status, diabetes, asthma/COPD, rheumatic diseases * Cholesterol levels: Total cholesterol, LDL, HDL * ECG and Bone Mineral Density (BMD) The analysis will evaluate the association between these factors and treatment-related complications, adjusting for thyroid hormone levels. Incidence rates of complications at follow-up will be compared using Chi-square, Fisher's exact test, or Generalized Estimating Equations (GEE). |
| Secondary | Predictors of TSH levels and proper thyroid hormone dosage | at 3,5years after enrollment | This study will identify factors that predict changes in thyroid hormone levels (TSH, free T4, total T3, or free T3) and predict the required thyroid medication dosing. The factors under include: * Demographic Factors: Sex, age, comorbidities, smoking status, body mass index (BMI), weight, and current medications * Thyroid Function: Pre-existing thyroid disorders, and the presence of thyroiditis The analysis will evaluate the association between these factors and changes in thyroid hormone levels, as well as predict the necessary adjustments in thyroid hormone dosing, using multiple regression analysis. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06971965
GET https://conductscience.org/api/trials/v1/NCT06971965/registered